Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Total Current Liabilities (2022 - 2025)

Historic Total Current Liabilities for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $8.1 million.

  • Corvus Pharmaceuticals' Total Current Liabilities fell 8260.14% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year decrease of 8260.14%. This contributed to the annual value of $35.4 million for FY2024, which is 41538.8% up from last year.
  • According to the latest figures from Q3 2025, Corvus Pharmaceuticals' Total Current Liabilities is $8.1 million, which was down 8260.14% from $8.5 million recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Total Current Liabilities peaked at $46.4 million during Q3 2024, and registered a low of $6.7 million during Q1 2024.
  • Over the past 4 years, Corvus Pharmaceuticals' median Total Current Liabilities value was $9.3 million (recorded in 2022), while the average stood at $13.5 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 53578.57% in 2024, then tumbled by 8260.14% in 2025.
  • Corvus Pharmaceuticals' Total Current Liabilities (Quarter) stood at $10.8 million in 2022, then plummeted by 36.11% to $6.9 million in 2023, then skyrocketed by 415.39% to $35.4 million in 2024, then crashed by 77.19% to $8.1 million in 2025.
  • Its Total Current Liabilities was $8.1 million in Q3 2025, compared to $8.5 million in Q2 2025 and $9.3 million in Q1 2025.